Streetbeat News

MKKGY

Merck KGAA

https://www.merckgroup.com/

CEO

Stefan Oschmann

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

29.41

Mkt cap

64B

Volume

26K

High

29.67

P/E Ratio

22.54

52-wk high

39.17

Low

29.41

Div yield

0.02

52-wk low

28.96

The article discusses whether Merck KGaA (MKKGY) is currently a great value stock, focusing on the Zacks Rank system which emphasizes earnings estimates and revisions.

Portfolio Pulse from

November 11, 2024 | 4:00 pm

C4 Therapeutics has signed a license agreement with Merck KGaA to discover two targeted protein degraders against oncogenic proteins. C4 Therapeutics will receive $16M upfront and could get up to $740M in milestone payments.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:05 pm

Pfizer Inc has received all necessary regulatory approvals to complete its $43 billion acquisition of Seagen Inc. To address FTC concerns, Pfizer agreed to donate Bavencio royalties to the American Association for Cancer Research. Pfizer will reorganize into three divisions, with the Pfizer Oncology Division integrating oncology operations from both companies. Merck KGaA regained rights to Bavencio, replacing profit share with a 15% royalty to Pfizer. Pfizer's Angela Hwang will leave the company, and the new structure will be effective January 1, 2024. Pfizer will provide financial guidance for 2024 in an upcoming webcast.

Portfolio Pulse from Vandana Singh

December 12, 2023 | 6:04 pm

Repligen Corporation (RGEN) has agreed to acquire Sweden-based Metenova, a move that is expected to expand Repligen's market reach and enhance its capabilities in fluid management. The acquisition is projected to contribute significantly to Repligen's revenues and margins from 2023 onwards. The deal is also expected to give Repligen a competitive edge against rivals like Merck KGaA (MKGAF, MKKGY).

Portfolio Pulse from Vandana Singh

September 26, 2023 | 7:07 pm

Merck KGa Germany reported a 4.8% decline in Q2 sales to €5.3 billion. Despite strong growth in the Healthcare sector, Group EBITDA pre declined by 12.8% to €1.55 billion due to decreased sales volumes and lower share of higher-margin products. The company has updated its 2023 forecast, expecting an organic sales growth of -2% to +2% and an organic decline in EBITDA pre by -9% to -3%. Both net sales and EBITDA pre are likely to be impacted by negative foreign exchange effects.

Portfolio Pulse from Vandana Singh

August 04, 2023 | 1:45 pm

The World Health Organization (WHO) has published new editions of the Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc), which include new medicines for various diseases. However, Novo Nordisk's obesity drug Saxenda was not included due to uncertain long-term clinical benefit and safety. Other drugs included in the list are from EMD Serono, Merck KGaA, Teva Pharmaceuticals, Roche Holdings, Ridgeback Biotherapeutics, and Regeneron Pharmaceuticals.

Portfolio Pulse from Vandana Singh

July 26, 2023 | 2:24 pm

RBC Capital Markets has downgraded Abcam PLC (NASDAQ:ABCM) from Outperform to Sector Perform with a price target of $22, down from $23. The downgrade is due to activist investor engagement and potential bid anticipation, which may cause share volatility. Major players in the life science tools space, such as Thermo Fisher Scientific, Danaher Corporation, Merck KGaA, Agilent Technologies, Bio-Techne Corp, and Revvity Inc, could be interested in Abcam.

Portfolio Pulse from Vandana Singh

June 20, 2023 | 6:37 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.